Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44396   clinical trials with a EudraCT protocol, of which   7408   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,396 result(s) found. Displaying page 1,739 of 2,220.
    «« First « Previous 1735  1736  1737  1738  1739  1740  1741  1742  1743  Next» Last»»
    EudraCT Number: 2020-000693-18 Sponsor Protocol Number: BreakB5/CA209-7WF Start Date*: 2020-12-07
    Sponsor Name:University Hospital Regensburg
    Full Title: Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with ...
    Medical condition: non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000304-14 Sponsor Protocol Number: GlioVax Start Date*: 2018-03-06
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma
    Medical condition: newly diagnosed glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005893-93 Sponsor Protocol Number: 00909043 Start Date*: 2021-09-21
    Sponsor Name:Uniwersytet Medyczny w Białymstoku
    Full Title: A randomized, double-blind, placebo-controlled study evaluating levosimendan re-infusions in patients with severe heart failure with reduced left ventricular ejection fraction.
    Medical condition: Ambulatory Heart Failure Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10074631 Systolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000972-88 Sponsor Protocol Number: MK3475-062 Start Date*: 2015-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
    Full Title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cispla...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) LV (Completed) NL (Completed) ES (Completed) CZ (Completed) FR (Completed) AT (Completed) HU (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005136-30 Sponsor Protocol Number: MK-6024-001 Start Date*: 2021-08-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
    Medical condition: Nonalcoholic Fatty Liver Disease
    Disease: Version SOC Term Classification Code Term Level
    22.0 10019805 - Hepatobiliary disorders 10082249 Nonalcoholic fatty liver disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006679-41 Sponsor Protocol Number: V116-006 Start Date*: 2022-08-22
    Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.
    Full Title: A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older
    Medical condition: Pneumococcal disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-002192-11 Sponsor Protocol Number: 15-08-2022 Start Date*: 2022-11-24
    Sponsor Name:Pirkanmaan sairaanhoitopiiri
    Full Title: Selän alueen poikkeava aktiivisuus servikaalisessa dystoniassa
    Medical condition: Servikaalinen dystonia, jossa poikkeavaa lihasaktiivisuutta esiintyy kaulan alueen lihaksissa aiheuttaen tyypillisiä virheasentoja kuten pään kiertymistä, kallistumista ja vapinaa. Servikaalista d...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001257-27 Sponsor Protocol Number: S61444 Start Date*: 2018-05-22
    Sponsor Name:KU Leuven
    Full Title: Cognitive brain circuits and the spread of tau in vivo in humans
    Medical condition: Alzheimer disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002370-31 Sponsor Protocol Number: IMA203-101 Start Date*: 2020-03-10
    Sponsor Name:Immatics US InC
    Full Title: Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients wi...
    Medical condition: Recurrent and / or refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006621-22 Sponsor Protocol Number: COVIC-19-G Start Date*: 2022-02-14
    Sponsor Name:DRK-Blutspendedienst Baden-Württemberg - Hessen gGmbH
    Full Title: A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new path...
    Medical condition: Clinically Vulnerable Individuals with Mild COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 10022891 - Investigations 10084355 COVID-19 virus test positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000688-57 Sponsor Protocol Number: AROAPOC3-2002 Start Date*: 2021-11-10
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia
    Medical condition: Mixed Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10027763 Mixed hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003015-34 Sponsor Protocol Number: LDOS003 Start Date*: 2018-04-12
    Sponsor Name:Helix BioPharma Corp
    Full Title: A Phase II Open-Label, Randomized Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Lung Adenocarcinoma
    Medical condition: Lung adenocarcinoma chemotherapy naive or recurrent for which vinorelbine/cisplatin would be appropriate therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025031 Lung adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000145-39 Sponsor Protocol Number: V59_66 Start Date*: 2013-07-31
    Sponsor Name:Novartis Vaccines and Diagnostics s.r.l
    Full Title: A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Health...
    Medical condition: To demonstrate non-inferiority of MenACWY vaccine to that of MenC vaccine given to healthy toddlers, as measured by the percentage of subjects with serum bactericidal assay using human complement...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001138-32 Sponsor Protocol Number: 208887 Start Date*: 2020-09-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refra...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Trial now transitioned) NL (Completed) ES (Temporarily Halted) NO (Trial now transitioned) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001586-21 Sponsor Protocol Number: 5FUdPDT78842 Start Date*: 2021-09-22
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Does 4% 5-fluorouracil pre-treatment improve the efficacy of daylight photodynamic therapy for actinic keratoses – a randomized controlled study
    Medical condition: Actinic keratosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10041304 Solar keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000242-17 Sponsor Protocol Number: Protocol_PPB_TKA_14012021 Start Date*: 2021-03-12
    Sponsor Name:Region Hospital Silkeborg
    Full Title: The effect of the popliteal plexus block on postoperative opioid consumption, pain, muscle strength and mobilization after total knee arthroplasty - a randomized, controlled, blinded study
    Medical condition: Postoperative pain following a total knee arthroplasty surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-005111-14 Sponsor Protocol Number: HPE-4/LCR Start Date*: 2019-04-25
    Sponsor Name:Kepler Universitätsklinikum, Medcampus III, Klinik für Interne 2
    Full Title: First-line Treatment of Helicobacter pylori with the Probiotic Lactobacillus casei rhamnosus LCR35 Alone or in Combination with a Levofloxacin-based Sequential Therapy: A Randomized, Placebo-contro...
    Medical condition: Helicobacter pylori infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001213-36 Sponsor Protocol Number: ISTH-02-211 Start Date*: 2021-06-20
    Sponsor Name:Isarna Therapeutics GmbH
    Full Title: TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study
    Medical condition: Neovascular age-related macular degeneration (nAMD) Diabetic Macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001702-88 Sponsor Protocol Number: 011-007 Start Date*: 2006-08-07
    Sponsor Name:Novacea, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)
    Medical condition: For the treatment of metastatic androgen independent prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Ongoing) HU (Prematurely Ended) CZ (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005461-19 Sponsor Protocol Number: 11/06/OXD/TP3 Start Date*: 2006-12-20
    Sponsor Name:Zentiva a.s.
    Full Title: A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Tolerability and Safety of ANTIRIN® nasal spray and drops in two Age Groups of Children with Acute Rhinitis
    Medical condition: Rinitis acuta
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1735  1736  1737  1738  1739  1740  1741  1742  1743  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 03 18:46:21 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA